Pieris Pharmaceuticals, Inc.

NASDAQ
PIRS
Stock
Yield per half year: -19.19%
Dividend yield: 0%
Sector: Healthcare

Share chart Pieris Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis.

more details
The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2015-04-13
ISIN US7207951036
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Цена ао 13.6
Change price per day: 0% (13.6)
Change price per week: 0% (13.6)
Change price per month: 0% (13.6)
Change price per 3 month: 0% (13.6)
Change price per half year: -19.19% (16.83)
Change price per year: +41.67% (9.6)
Change price per 3 year: +700% (1.7)
Change price per 5 year: +481.2% (2.34)
Change price per year to date: 0% (13.6)
All parameters

Grade

Underestimation
Title Value Grade
P/S 0.3316 10
P/BV 0.5305 10
P/E 0 0
EV/EBITDA 0.2277 10
Total: 6.25
Efficiency
Title Value Grade
ROA, % -63.45 0
ROE, % -91.72 0
Total: 0
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0
Debt
Title Value Grade
Debt/EBITDA -0.9315 10
Total: 9.6
Growth impulse
Title Value Grade
Yield Revenue, % -7.54 0
Yield Ebitda, % -12.79 0
Yield EPS, % 4546.31 10
Total: 2.2
More

Main owners

Institutions Volume Share, %
BVF Inc. 20 609 863 20.83
Lynx1 Capital Management Lp 9 775 849 9.88
Citadel Advisors Llc 1 189 887 1.2
Renaissance Technologies, LLC 1 065 007 1.08
Blackrock Inc. 1 037 747 1.05
Acadian Asset Management. LLC 962 358 0.97
Vanguard Group Inc 907 390 0.92
Geode Capital Management, LLC 761 444 0.77
CM Management, LLC 750 000 0.76
Northern Trust Corporation 243 592 0.25

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Stephen S. Yoder J.D. CEO, President & Director 744.13k 1976 (49 years)
Mr. Thomas Bures Senior VP, CFO & Treasurer 487.5k 1975 (50 years)
Maria Kelman Executive Director of Investor Relations N/A
Dr. Shane Olwill Ph.D. Senior VP & Chief Development Officer 463.91k 1976 (49 years)
Mr. Prompong Chaikul Chief Supply Chain Officer N/A 1987 (38 years)

About company

Address: United States, Boston. MA, 225 Franklin Street - Open in google maps, Open in yandex maps
Website: https://www.pieris.com